These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33307874)

  • 1. RNA therapeutics for retinal diseases.
    Gemayel MC; Bhatwadekar AD; Ciulla T
    Expert Opin Biol Ther; 2021 May; 21(5):603-613. PubMed ID: 33307874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases.
    Germain ND; Chung WK; Sarmiere PD
    Mol Aspects Med; 2023 Jun; 91():101148. PubMed ID: 36257857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.
    Xue K; MacLaren RE
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1163-1170. PubMed ID: 32741234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA therapeutics in ophthalmology - translation to clinical trials.
    Gupta A; Kafetzis KN; Tagalakis AD; Yu-Wai-Man C
    Exp Eye Res; 2021 Apr; 205():108482. PubMed ID: 33548256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.
    Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ
    Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of gene therapy for treatment of age-related macular degeneration.
    Askou AL
    Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease.
    Moore SM; Skowronska-Krawczyk D; Chao DL
    Adv Exp Med Biol; 2019; 1185():85-89. PubMed ID: 31884593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.
    Singh S; Narang AS; Mahato RI
    Pharm Res; 2011 Dec; 28(12):2996-3015. PubMed ID: 22033880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference silencing the transcriptional message: aspects and applications.
    Karkare S; Daniel S; Bhatnagar D
    Appl Biochem Biotechnol; 2004 Oct; 119(1):1-12. PubMed ID: 15496724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Types of RNA therapeutics.
    Goleij P; Babamohamadi M; Rezaee A; Sanaye PM; Tabari MAK; Sadreddini S; Arefnezhad R; Motedayyen H
    Prog Mol Biol Transl Sci; 2024; 203():41-63. PubMed ID: 38360005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi in clinical studies.
    Kubowicz P; Żelaszczyk D; Pękala E
    Curr Med Chem; 2013; 20(14):1801-16. PubMed ID: 23432579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Great potential of small RNAs: RNA interference and microRNA].
    Vázquez-Ortiz G; Piña-Sánchez P; Salcedo M
    Rev Invest Clin; 2006; 58(4):335-49. PubMed ID: 17146945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA and shRNA expression vectors based on mRNA and miRNA processing.
    Wu P; Wilmarth MA; Zhang F; Du G
    Methods Mol Biol; 2013; 936():195-207. PubMed ID: 23007510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA therapeutics: Identification of novel targets leading to drug discovery.
    Qadir MI; Bukhat S; Rasul S; Manzoor H; Manzoor M
    J Cell Biochem; 2020 Feb; 121(2):898-929. PubMed ID: 31478252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases.
    Pandey M; Ojha D; Bansal S; Rode AB; Chawla G
    Mol Aspects Med; 2021 Oct; 81():101003. PubMed ID: 34332771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA silencing and HIV: a hypothesis for the etiology of the severe combined immunodeficiency induced by the virus.
    Ludwig LB
    Retrovirology; 2008 Sep; 5():79. PubMed ID: 18786256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference and cancer therapy.
    Wang Z; Rao DD; Senzer N; Nemunaitis J
    Pharm Res; 2011 Dec; 28(12):2983-95. PubMed ID: 22009588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.